Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease-Reference-Cited by-同舟云学术

Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease

Published:2018-06-03 Issue:15 Volume:175 Page:3080-3089
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British Journal of Pharmacology

Author:

O'Hara Darren M¹^ORCID,Kalia Suneil K¹²,Kalia Lorraine V¹³⁴⁵^ORCID

Affiliation:

1. Krembil Research Institute, Toronto Western Hospital; University Health Network; Toronto Canada

2. Division of Neurosurgery, Department of Surgery; University of Toronto; Toronto Canada

3. Division of Neurology, Department of Medicine; University of Toronto; Toronto Canada

4. Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital; University Health Network; Toronto Canada

5. Tanz Centre for Research in Neurodegenerative Diseases; University of Toronto; Toronto Canada

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.14345/fullpdf

Reference74 articles.

1. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors;Alexander;Br J Pharmacol,2017a

2. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes;Alexander;Br J Pharmacol,2017b

3. Alzforum 2017 Alpha-Synuclein Antibodies Enter Phase 2, Sans Biomarker Https://Www.Alzforum.Org/News/Conference-Coverage/Synuclein-Antibodies-Enter-Phase-2-Sans-Biomarker

4. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts;Bhatt;J Parkinsons Dis,2013

5. O-Glcnac cycling: a link between metabolism and chronic disease;Bond;Annu Rev Nutr,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico study on graphene quantum dots modified with various functional groups inhibiting α‑synuclein dimerization;Journal of Colloid and Interface Science;2024-08

2. Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease;WIREs Nanomedicine and Nanobiotechnology;2023-05-08

3. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease;Nature Communications;2023-04-19

4. The relevance of synuclein autoantibodies as a biomarker for Parkinson's disease;Molecular and Cellular Neuroscience;2022-07

5. Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification;European Journal of Medicinal Chemistry;2022-07